Vencorex is pleased to announce the completion of its industrial projects that include expansion of the monomer (HDI and IPDI) capacity in France (Pont de Claix site), a new derivatives unit, Tolonate™, in Thailand (Rayong plant), a new waterborne derivatives, Easaqua™, production chain in the US (Texas, Freeport site).
“Vencorex teams have been fully committed to these industrial projects and delivered on expected targets. The Sales and Marketing teams are now focusing to serve the market with capacity that follows the growth demand of our customers.” says Xavier Fournier, Vencorex CEO.
The completion of major product expansions will allow the company to become a truly global company with a very strong monomer integration. The value chain will be even further enhanced in months to come when the company completes another project on the modernization of the electrolysis chlorine production in France. With this strong foundation established, Vencorex will be in the position to invest further in derivative line expansions where we see growth. Along with the production assets, other enablers will also be greatly enhanced including marketing and sales, as well as research & development infrastructures.
Vencorex announced in 2014 its long term strategic ambition. This strategy is based on focusing its activities toward specialty isocyanates. To achieve this long term ambition, Vencorex has enhanced its footprint on production capacities, commercial activities and R&D innovation.
For further information, please contact:
Vencorex holding: Sandrine Nabet, Market Communications Manager – Phone: +33 6 80 48 18 47